Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q4 2025 Earnings Presentation
16 slides from Syndax Pharmaceuticals's earnings presentation, Feb 26, 2026
Slide 1: Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter and Full Year 2025 Financial Results February 26, 2026
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Strong commercial and pipeline execution positions Syndax for continued growth in 2026 and beyond
Strong commercial and pipeline execution positions Syndax for continued growth in 2026 and beyond Commercial Results Pipeline Progress 4Q25 2025 Achieved 3rd FDA approval in ~1 year $44.2M $124.8M 1st to initiate a pivotal 1L menin trial, Net revenue +38% q/q positioning Syndax to be 1st to the 1L $
Slide 4: Excellent first year Revuforj results with strong growth in 4Q25 following label expansion
Excellent first year Revuforj results with strong growth in 4Q25 following label expansion Accelerating demand and expansion of prescriber base throughout 4Q25 4Q25 END OF 2025 Net $44.2M $124.8M revenue 38% q/q growth 2025 net revenue TRx growth driven by new NPM1 patients and building use in KMT2A
Slide 5: Evolving clinical practice driving continued Revuforj growth in 2026
Evolving clinical practice driving continued Revuforj growth in 2026 1 2 3 Growing adoption in Robust transplant rate Use in early lines of R/R NPM1m AML in KMT2Ar and growing treatment and growing usage post-transplant combination use Early indicators suggest ≥30% ~33% of KMT2A patients have ~70% o
Slide 6: Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia
Current Revuforj indications unlock $2B+ TAM in R/R acute leukemia $5B+ TAM across R/R and 1L With the largest addressable U.S. Market Opportunity ($ B) population and anticipated duration of therapy, Revuforj is poised to become the largest targeted AML therapy $2B+ TAM in R/R Addressable AML popul
Slide 7: Remarkable first year results highlight the importance of Niktimvo to patients and Syndax
Remarkable first year results highlight the importance of Niktimvo to patients and Syndax Strong demand underscores Niktimvo’s ability to address inflammation and fibrosis 4Q25 FY 2025 Net revenue $56.0M $151.6M to INCY 22% q/q growth Results surpass launch benchmark in 3L+ cGVHD Collaboration $19.4
Slide 8: Multiple drivers supporting continued Niktimvo growth in 2026
Multiple drivers supporting continued Niktimvo growth in 2026 1 2 33 Continued adoption Potential for extended Robust prescriber base in 4L and growing treatment durations to and strong commercial usage in 3L cGVHD address chronic disease synergies ~60-70% of pts who started ~20% share of 3L+ cGVHD
Slide 9: Initial Niktimvo indication represents a $2B U.S. market opportunity
Initial Niktimvo indication represents a $2B U.S. market opportunity, with substantial opportunities for label and geographic expansion ~17,000 U.S. cGVHD patients1 $5B+ TAM $2B TAM with initial Niktimvo indication ~6,500 currently treated 3L+ U.S. cGVHD patients Ongoing combo trials could support f
Slide 10: Laser-focused on unlocking the full potential of menin and CSF-1R inhibition
Laser-focused on unlocking the full potential of menin and CSF-1R inhibition Revumenib (select trials) FDA Ph 1 Ph 2 Ph 3 Setting Study Name Regimen NPM1m KMT2Ar NUP98r Approved AUGMENT-101 Rev mono ● ● ✓ Global enrollment underway in pivotal 1L R/R AUGMENT-102 Rev + IC ● ● ● trials with dual primar
Slide 11: A promising new target in IPF: CSF-1R inhibition of monocytes and macrophages
A promising new target in IPF: CSF-1R inhibition of monocytes and macrophages • Monocyte-derived alveolar macrophages play a key role in lung fibrosis1 • Colony stimulating factor-1 receptor (CSF-1R) signaling is a key regulator of monocytes and macrophages2 • Blocking CSF-1R with axatilimab: o Redu
Slide 12: Multiple lines of evidence support the potential for axatilimab in IPF
Multiple lines of evidence support the potential for axatilimab in IPF Bleomycin models show Higher monocyte levels are Remarkable antifibrotic activity observed with reduction in lung fibrosis with associated with shorter OS in IPF1 axatilimab in cGVHD across all organs studied3 axatilimab surrogat
Slide 13: Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26
Topline data from MAXPIRe Phase 2 trial of axatilimab in IPF anticipated in 4Q26 A randomized, double-blind, placebo-controlled, multi-center international trial Key eligibility criteria: 26-week treatment • ≥40 yrs of age Axatilimab 0.3 mg/kg Q2W • HRCT confirming IPF diagnosis (n≈90) • FVC ≥45% of
Slide 14: Strong financial position driven by growing revenue and stable expense outlook
Strong financial position driven by growing revenue and stable expense outlook On the road to profitability Financial Summary Three Months Ended Year Ended ($ in millions) Dec 31 Dec 31 2025 2024 2025 2024 Product revenue, net 44.2 7.7 124.8 7.7 AS OF 31 DEC 2025: Collaboration revenue, net 19.4 — 4
Slide 15: Proven execution supports continued focus on revenue growth, pipeline progress, and data generation
Proven execution supports continued focus on revenue growth, pipeline progress, and data generation 2026 Anticipated Milestones 2025 Key Accomplishments Advance global enrollment in pivotal 1L trials of revumenib ✓ Executed two strong product launches Publish & present industry leading clinical data
Slide 16: Slide 16
Syndax Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix